Green Planet Bioengineering Co., Ltd. reported its financial results for the nine months ended September 30, 2024, revealing a net loss of $22,753, a decrease from the net loss of $34,120 for the same period in 2023. The company’s net loss for the three months ended September 30, 2024, was $7,752, compared to a loss of $5,425 in the prior year. The accumulated deficit as of September 30, 2024, stands at $1,081,963, up from $1,059,210 at the end of 2023.

The company continues to operate as a public reorganized shell corporation with no active business operations. Its expenses for the nine months ended September 30, 2024, were limited to accounting and filing fees. The company reported a working capital deficit of $452,343 as of September 30, 2024, compared to $429,590 at the end of 2023.

Cash flows used by operating activities for the nine months ended September 30, 2024, were $(23,753), an improvement from $(30,120) in the same period of 2023. However, cash flows provided by financing activities decreased to $23,753 from $30,120 year-over-year. The company has received interest-free, unsecured advances from a related party totaling $448,343, which are repayable upon demand. An additional $4,000 was advanced by the related party subsequent to September 30, 2024.

As of September 30, 2024, the company has not issued any shares of Series A preferred stock or common stock during the nine-month period. It is authorized to issue 10,000,000 shares of Series A preferred stock and 250,000,000 shares of common stock, both with a par value of $0.001 per share.

The company’s ability to continue as a going concern is heavily reliant on the support from a related party, raising substantial doubt about its viability for the next twelve months. There have been no off-balance sheet arrangements that materially affect its financial condition or operations, and no material changes in market risks have been reported since the last Annual Report on Form 10-K for the year ended December 31, 2023.